The estimated Net Worth of Graham K Cooper is at least $236 mil dollars as of 6 July 2021. Mr. Cooper owns over 2,614 units of Unity Biotechnology Inc stock worth over $3,660 and over the last 13 years he sold UBX stock worth over $0. In addition, he makes $232,580 as Independent Director at Unity Biotechnology Inc.
Graham has made over 2 trades of the Unity Biotechnology Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 2,614 units of UBX stock worth $44,438 on 6 July 2021.
The largest trade he's ever made was exercising 12,045 units of Unity Biotechnology Inc stock on 28 June 2021 worth over $204,765. On average, Graham trades about 586 units every 0 days since 2012. As of 6 July 2021 he still owns at least 2,614 units of Unity Biotechnology Inc stock.
You can see the complete history of Mr. Cooper stock trades at the bottom of the page.
Graham K. Cooper CPA serves as Independent Director of the Company. From March 2018 until May 2019, Mr. Cooper served as the Chief Operating Officer and Chief Financial Officer of Assembly Biosciences, Inc. Mr. Cooper previously served as the Chief Financial Officer of Receptos, Inc., from February 2013 until its acquisition by Celgene in August 2015 and Chief Financial Officer of Geron Corporation from January 2012 to December 2012. From May 2006 until March 2011, Mr. Cooper served as Chief Financial Officer of Orexigen Therapeutics, Inc. Prior to that, Mr. Cooper held roles of increasing responsibility at Deutsche Bank Securities, an investment bank, from August 1997 to February 2006, including Director, Health Care Investment Banking. He began his career as an accountant at Deloitte & Touche, and was previously a C.P.A. Mr. Cooper currently serves on the board of directors of Beam Therapeutics, Inc., a public biotechnology company, Kezar Life Sciences, Inc., a public biotechnology company, and Applied Molecular Transport Inc., a private biotechnology company. Mr. Cooper received a B.A. in Economics from the University of California at Berkeley and an M.B.A. from the Stanford Graduate School of Business.
As the Independent Director of Unity Biotechnology Inc, the total compensation of Graham Cooper at Unity Biotechnology Inc is $232,580. There are 8 executives at Unity Biotechnology Inc getting paid more, with Keith Leonard having the highest compensation of $3,270,820.
Graham Cooper is 50, he's been the Independent Director of Unity Biotechnology Inc since 2017. There are 19 older and 3 younger executives at Unity Biotechnology Inc. The oldest executive at Unity Biotechnology Inc is David Lacey, 67, who is the Independent Director.
Graham's mailing address filed with the SEC is C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 7 years, insiders at Unity Biotechnology Inc have traded over $9,012,473 worth of Unity Biotechnology Inc stock and bought 3,200 units worth $28,480 . The most active insiders traders include Kristina Burow, Robert Nelsen, eNathaniel E David. On average, Unity Biotechnology Inc executives and independent directors trade stock every 54 days with the average trade being worth of $65,316. The most recent stock trade was executed by Alexander Hieu Nguyen on 2 August 2024, trading 154 units of UBX stock currently worth $236.
unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.
Unity Biotechnology Inc executives and other stock owners filed with the SEC include: